Neuronetics, Inc.
American company
STIM Nasdaq
ISIN US64131A1051 SEC CIK 1227636 LEI 549300T0911ILTTG7P06
Follow Neuronetics
Weekly email: filings, results
Revenue, last quarter
$42M
+12.5% vs same quarter last year
Net income
−$1.7M
+81.3% vs same quarter last year
EPS, diluted
−$0.02
+84.6% vs same quarter last year
Operating cash flow
$1.2M
+257.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $149.2M | −$39M |
| FY24 | $74.9M | −$43.7M |
| FY23 | $71.3M | −$30.2M |
| FY22 | $65.2M | −$37.2M |
| FY21 | $55.3M | −$31.2M |
| FY20 | $49.2M | −$27.5M |
| FY19 | $62.7M | −$29M |
| FY18 | $52.8M | −$24.1M |
| FY17 | $40.4M | −$16.1M |
| FY16 | $34.2M | −$11.2M |
| FY15 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 48.5% | −21.1% | −26.1% |
| FY24 | 72.3% | −46.2% | −58.4% |
| FY23 | 72.5% | −42.8% | −42.3% |
| FY22 | 76.3% | −53.8% | −57% |
| FY21 | 78.9% | −49.8% | −56.4% |
| FY20 | 76.5% | −45.3% | −55.7% |
| FY19 | 75.4% | −43% | −46.4% |
| FY18 | 76.4% | −37.6% | −45.7% |
| FY17 | 76.2% | −33.7% | −39.7% |
| FY16 | 80.7% | −27.3% | −32.8% |
| FY15 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$21.2M |
| FY24 | −$32.5M |
| FY23 | −$34.4M |
| FY22 | −$34M |
| FY21 | −$30.3M |
| FY20 | −$29.1M |
| FY19 | −$31.3M |
| FY18 | −$21.6M |
| FY17 | −$11.7M |
| FY16 | −$8.9M |
| FY15 | - |
- Neuronetics
- Healthcare median
Show the numbers
| Year | Neuronetics | Healthcare median |
|---|---|---|
| FY25 | −26.1% | −30.6% |
| FY24 | −58.4% | −47% |
| FY23 | −42.3% | −58% |
| FY22 | −57% | −80.4% |
| FY21 | −56.4% | −71.8% |
| FY20 | −55.7% | −62.2% |
| FY19 | −46.4% | −46.2% |
| FY18 | −45.7% | −49.6% |
| FY17 | −39.7% | −45.9% |
| FY16 | −32.8% | −36% |
| FY15 | - | −37.8% |